Literature DB >> 24778415

Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.

Denise L Cecil1, Gregory E Holt1, Kyong Hwa Park1, Ekram Gad1, Lauren Rastetter1, Jennifer Childs1, Doreen Higgins1, Mary L Disis2.   

Abstract

Immunization against self-tumor antigens can induce T-regulatory cells, which inhibit proliferation of type I CD4(+) T-helper (TH1) and CD8(+) cytotoxic T cells. Type I T cells are required for potent antitumor immunity. We questioned whether immunosuppressive epitopes could be identified and deleted from a cancer vaccine targeting insulin-like growth factor-binding protein (IGFBP-2) and enhance vaccine efficacy. Screening breast cancer patient lymphocytes with IFN-γ and interleukin (IL)-10 ELISPOT, we found epitopes in the N-terminus of IGFBP-2 that elicited predominantly TH1 whereas the C-terminus stimulated TH2 and mixed TH1/TH2 responses. Epitope-specific TH2 demonstrated a higher functional avidity for antigen than epitopes, which induced IFN-γ (P = 0.014). We immunized TgMMTV-neu mice with DNA constructs encoding IGFBP-2 N-and C-termini. T cell lines expanded from the C-terminus vaccinated animals secreted significantly more type II cytokines than those vaccinated with the N-terminus and could not control tumor growth when infused into tumor-bearing animals. In contrast, N-terminus epitope-specific T cells secreted TH1 cytokines and significantly inhibited tumor growth, as compared with naïve T cells, when adoptively transferred (P = 0.005). To determine whether removal of TH2-inducing epitopes had any effect on the vaccinated antitumor response, we immunized mice with the N-terminus, C-terminus, and a mix of equivalent concentrations of both vaccines. The N-terminus vaccine significantly inhibited tumor growth (P < 0.001) as compared with the C-terminus vaccine, which had no antitumor effect. Mixing the C-terminus with the N-terminus vaccine abrogated the antitumor response of the N-terminus vaccine alone. The clinical efficacy of cancer vaccines targeting self-tumor antigens may be greatly improved by identification and removal of immunosuppressive epitopes. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24778415      PMCID: PMC4037234          DOI: 10.1158/0008-5472.CAN-13-3286

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Interpreting the biological relevance of bioinformatic analyses with T-DNA sequence for protein allergenicity.

Authors:  B Harper; S McClain; E W Ganko
Journal:  Regul Toxicol Pharmacol       Date:  2012-06-02       Impact factor: 3.271

Review 2.  Clinical evaluation of TRICOM vector therapeutic cancer vaccines.

Authors:  Ravi A Madan; Marijo Bilusic; Christopher Heery; Jeffrey Schlom; James L Gulley
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

3.  Maximizing the retention of antigen specific lymphocyte function after cryopreservation.

Authors:  Mary L Disis; Corazon dela Rosa; Vivian Goodell; Ling-Yu Kuan; Jennie C C Chang; Kristina Kuus-Reichel; Timothy M Clay; H Kim Lyerly; Sonny Bhatia; Smita A Ghanekar; Vernon C Maino; Holden T Maecker
Journal:  J Immunol Methods       Date:  2005-10-21       Impact factor: 2.303

4.  TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice.

Authors:  H Maeda; A Shiraishi
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

5.  Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice.

Authors:  Keith L Knutson; Bond Almand; Yushe Dang; Mary L Disis
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

6.  Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.

Authors:  Jinming Li; Yanli Sun; Tingting Jia; Rui Zhang; Kuo Zhang; Lunan Wang
Journal:  Int J Cancer       Date:  2013-10-08       Impact factor: 7.396

7.  TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.

Authors:  Emmanuella Guenova; Rei Watanabe; Jessica E Teague; Jennifer A Desimone; Ying Jiang; Mitra Dowlatshahi; Christoph Schlapbach; Knut Schaekel; Alain H Rook; Marianne Tawa; David C Fisher; Thomas S Kupper; Rachael A Clark
Journal:  Clin Cancer Res       Date:  2013-06-19       Impact factor: 12.531

8.  Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells.

Authors:  Magis Mandapathil; Carmen Visus; Olivera J Finn; Stephan Lang; Theresa L Whiteside
Journal:  Oncoimmunology       Date:  2013-07-03       Impact factor: 8.110

9.  A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.

Authors:  Lisa M Ebert; Sarah E MacRaild; Damien Zanker; Ian D Davis; Jonathan Cebon; Weisan Chen
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240

10.  HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients.

Authors:  Hans-Henning Schmidt; Yingzi Ge; Felix J Hartmann; Heinke Conrad; Felix Klug; Sina Nittel; Helga Bernhard; Christoph Domschke; Florian Schuetz; Christof Sohn; Philipp Beckhove
Journal:  Oncoimmunology       Date:  2013-05-15       Impact factor: 8.110

View more
  24 in total

1.  Trial watch: Naked and vectored DNA-based anticancer vaccines.

Authors:  Norma Bloy; Aitziber Buqué; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

Review 2.  Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer.

Authors:  William C Watt; Denise L Cecil; Mary L Disis
Journal:  Semin Immunopathol       Date:  2016-12-14       Impact factor: 9.623

3.  Th1 epitope selection for clinically effective cancer vaccines.

Authors:  Mary L Disis; William C Watt; Denise L Cecil
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

Review 4.  Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.

Authors:  Jason Lohmueller; Olivera J Finn
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

5.  Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo.

Authors:  Denise L Cecil; Meredith Slota; Megan M O'Meara; Benjamin C Curtis; Ekram Gad; Yushe Dang; Daniel Herendeen; Lauren Rastetter; Mary L Disis
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

6.  Designing vaccines to prevent breast cancer recurrence or invasive disease.

Authors:  Sasha E Stanton; Mary L Disis
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

Review 7.  Breast cancer vaccines for treatment and prevention.

Authors:  Mary L Disis; Denise L Cecil
Journal:  Breast Cancer Res Treat       Date:  2021-11-30       Impact factor: 4.872

Review 8.  IGFBP2: integrative hub of developmental and oncogenic signaling network.

Authors:  Tao Li; M Elizabeth Forbes; Gregory N Fuller; Jiabo Li; Xuejun Yang; Wei Zhang
Journal:  Oncogene       Date:  2020-01-10       Impact factor: 9.867

9.  Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses.

Authors:  Denise L Cecil; John B Liao; Yushe Dang; Andrew L Coveler; Angela Kask; Yi Yang; Jennifer S Childs; Doreen M Higgins; Mary L Disis
Journal:  Clin Cancer Res       Date:  2021-09-15       Impact factor: 13.801

Review 10.  Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine.

Authors:  Jeanne Galaine; Christophe Borg; Yann Godet; Olivier Adotévi
Journal:  Vaccines (Basel)       Date:  2015-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.